title: Endometriotic implants regress in rat models treated with puerarin by decreasing estradiol level.
abstract: Phytoestrogens, which have a weak estrogenic effect, bind to estrogen receptors (ERs), thereby competing with estradiol, have an antiestrogenic effect on women of reproductive age with high estrogenic level. Herein, we examined the ability of the phytoestrogen Puerarin to treat endometriosis in rat models of endometriosis. In total, 75 adult, mature female Sprague-Dawley rats in which endometriotic implants were successfully induced by transplanting autologous endometrial tissue to ectopic sites were used in this study. Oral gavage of Puerarin (at doses of 600, 200, or 60 mg/kg per day) or Danazol (80 mg/kg per day) started 4 weeks after implantation. Control model rats received vehicle alone. After administration for 4 weeks, the weight of the ectopic implants, estradiol concentration, as well as ER-α and Aromatase P450 (P450arom) expression in different groups of rat tissues were evaluated after treatment. The endometriotic tissue weight and serum estrogen levels were significantly lower in high, medium, low dose of Puerarin and Danazol treatment groups than that in control group (P < .05 or P < .01). Low-dose Puerarin inhibited P450arom expression and significantly reduced estrogen levels in endometriotic tissue (P < .01). Three doses of Puerarin had no adverse effects on liver, kidney, and ovary, whereas high-dose Puerarin administration caused thinner bone trabecula with distortion and breakage and Danazol administration caused mild or moderate hepatic cell damage. These data demonstrate that Puerarin was able to effectively suppress the growth and development of ectopic endometrium in the rat endometriosis model, even at low doses, suggesting it may be an effective treatment for endometriosis.
authors.affiliation: Department of Chinese Traditional Medicine Gynecology, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai, People's Republic of China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Chen
authors.forename: Chao
authors.initials: C
authors.lastname: Chen
authors.forename: Shufang
authors.initials: S
authors.lastname: Shi
authors.forename: Jie
authors.initials: J
authors.lastname: Han
authors.forename: Jiaqi
authors.initials: J
authors.lastname: Wang
authors.forename: Jingjing
authors.initials: J
authors.lastname: Hu
authors.forename: Yuhuan
authors.initials: Y
authors.lastname: Liu
authors.forename: Zailong
authors.initials: Z
authors.lastname: Cai
authors.forename: Chaoqin
authors.initials: C
authors.lastname: Yu
mesh_terms: D000818:Animals; D004715:Endometriosis / Q000188:drug therapy* / Q000378:metabolism*; D004958:Estradiol / Q000032:analysis / Q000378:metabolism*; D047628:Estrogen Receptor alpha / Q000378:metabolism; D047629:Estrogen Receptor beta / Q000378:metabolism; D005260:Female; D007529:Isoflavones / Q000494:pharmacology*; D048789:Phytoestrogens / Q000494:pharmacology*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; D007529:Isoflavones; D048789:Phytoestrogens; D004958:Estradiol; C033607:puerarin